Trending Stock News

Bio-Rad Laboratories, Inc. (BIO) Reaches $290.15 52-Week High; Putnam Investments Has Lifted By $72.87 Million Its Nxp Semiconductors Nv (NXPI) Holding

Bio-Rad Laboratories, Inc. (NYSE:BIO) Logo

The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) hit a new 52-week high and has $316.26 target or 9.00% above today’s $290.15 share price. The 9 months bullish chart indicates low risk for the $8.60B company. The 1-year high was reported on May, 17 by Barchart.com. If the $316.26 price target is reached, the company will be worth $773.64M more. The stock decreased 0.53% or $1.55 during the last trading session, reaching $290.15. About 144,832 shares traded. Bio-Rad Laboratories, Inc. (NYSE:BIO) has risen 25.02% since May 17, 2017 and is uptrending. It has outperformed by 13.47% the S&P500.

Putnam Investments Llc increased Nxp Semiconductors Nv (NXPI) stake by 68.14% reported in 2017Q4 SEC filing. Putnam Investments Llc acquired 622,853 shares as Nxp Semiconductors Nv (NXPI)’s stock rose 4.13%. The Putnam Investments Llc holds 1.54M shares with $179.97M value, up from 914,144 last quarter. Nxp Semiconductors Nv now has $37.81B valuation. The stock increased 0.97% or $1.06 during the last trading session, reaching $109.9. About 1.22M shares traded. NXP Semiconductors N.V. (NASDAQ:NXPI) has risen 17.73% since May 17, 2017 and is uptrending. It has outperformed by 6.18% the S&P500.

Analysts await Bio-Rad Laboratories, Inc. (NYSE:BIO) to report earnings on August, 2. They expect $1.25 EPS, up 115.52% or $0.67 from last year’s $0.58 per share. BIO’s profit will be $37.03 million for 58.03 P/E if the $1.25 EPS becomes a reality. After $1.17 actual EPS reported by Bio-Rad Laboratories, Inc. for the previous quarter, Wall Street now forecasts 6.84% EPS growth.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company has market cap of $8.60 billion. The firm operates through two divisions, Life Science and Clinical Diagnostics. It has a 75.96 P/E ratio. The Life Science segment develops, makes, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

More notable recent Bio-Rad Laboratories, Inc. (NYSE:BIO) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway” on May 15, 2018, also Businesswire.com with their article: “Bio-Rad Reports First Quarter 2018 Financial Results” published on May 08, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy’s Revenue Miss, FDA Warns E-Liquid Makers Again” on May 11, 2018. More interesting news about Bio-Rad Laboratories, Inc. (NYSE:BIO) were released by: Businesswire.com and their article: “Bio-Rad to Report First-Quarter 2018 Financial Results” published on April 18, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer’s Trial …” with publication date: May 10, 2018.

Since December 14, 2017, it had 0 buys, and 1 sale for $1.24 million activity. TSINGOS CHRISTINE A sold $1.24M worth of Bio-Rad Laboratories, Inc. (NYSE:BIO) on Thursday, December 14.

Among 5 analysts covering Bio-Rad Laboratories (NYSE:BIO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Bio-Rad Laboratories has $300.0 highest and $143 lowest target. $233.50’s average target is -19.52% below currents $290.15 stock price. Bio-Rad Laboratories had 20 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) earned “Buy” rating by Jefferies on Friday, October 20. As per Wednesday, April 12, the company rating was maintained by Jefferies. The rating was maintained by Wells Fargo with “Outperform” on Wednesday, February 28. The firm earned “Buy” rating on Friday, April 28 by Jefferies. The rating was maintained by Jefferies on Wednesday, September 27 with “Buy”. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) earned “Hold” rating by C.L. King on Friday, February 16. Jefferies maintained Bio-Rad Laboratories, Inc. (NYSE:BIO) on Wednesday, September 7 with “Buy” rating. The stock of Bio-Rad Laboratories, Inc. (NYSE:BIO) has “Buy” rating given on Wednesday, November 29 by Wells Fargo. The stock has “Buy” rating by Jefferies on Friday, November 3. CL King downgraded Bio-Rad Laboratories, Inc. (NYSE:BIO) on Friday, February 16 to “Neutral” rating.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.35, from 0.78 in 2017Q3. It is positive, as 23 investors sold Bio-Rad Laboratories, Inc. shares while 89 reduced holdings. 44 funds opened positions while 82 raised stakes. 18.57 million shares or 0.31% more from 18.51 million shares in 2017Q3 were reported. Asset Mngmt holds 0.01% or 937 shares. Great West Life Assurance Co Can holds 11,586 shares. Citadel Advisors Ltd Company, a Illinois-based fund reported 185,096 shares. Daruma Cap Mngmt Ltd Co accumulated 15,478 shares. 2,970 are held by Btr Capital Management Inc. Natixis owns 0.01% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 7,638 shares. Credit Suisse Ag invested 0.01% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Cohen Cap holds 0.05% or 900 shares in its portfolio. Price T Rowe Associate Md holds 138,896 shares. Panagora Asset Mngmt Incorporated has invested 0% in Bio-Rad Laboratories, Inc. (NYSE:BIO). Employees Retirement Sys Of Texas, Texas-based fund reported 7,000 shares. Commonwealth Of Pennsylvania Public School Empls Retrmt Systems invested in 2,953 shares. Pacad holds 0.05% of its portfolio in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 1,000 shares. Putnam Invests Ltd reported 244,985 shares. Segall Bryant Hamill owns 0.15% invested in Bio-Rad Laboratories, Inc. (NYSE:BIO) for 28,924 shares.

Among 28 analysts covering NXP Semiconductors NV (NASDAQ:NXPI), 10 have Buy rating, 1 Sell and 17 Hold. Therefore 36% are positive. NXP Semiconductors NV had 72 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Pacific Crest with “Overweight” on Friday, April 8. Jefferies maintained NXP Semiconductors N.V. (NASDAQ:NXPI) rating on Monday, February 12. Jefferies has “Hold” rating and $120.0 target. Morgan Stanley initiated NXP Semiconductors N.V. (NASDAQ:NXPI) rating on Monday, October 12. Morgan Stanley has “Overweight” rating and $115 target. Stifel Nicolaus maintained NXP Semiconductors N.V. (NASDAQ:NXPI) rating on Friday, November 3. Stifel Nicolaus has “Hold” rating and $110.0 target. The stock has “Neutral” rating by Bank of America on Monday, June 27. The firm has “Hold” rating by Bernstein given on Thursday, May 3. The firm earned “Hold” rating on Thursday, May 3 by Oppenheimer. The company was initiated on Monday, April 11 by Nomura. The rating was upgraded by SunTrust to “Buy” on Friday, April 27. CLSA downgraded NXP Semiconductors N.V. (NASDAQ:NXPI) on Friday, October 28 to “Underperform” rating.

Bio-Rad Laboratories, Inc. (NYSE:BIO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *